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Abstract:	
	
A	major	determinant	of	pathogenicity	in	malaria	caused	by	Plasmodium	falciparum	is	the	
adhesion	of	parasite-infected	erythrocytes	to	the	vasculature	or	tissues	of	infected	
individuals.	This	occludes	blood	flow,	leads	to	inflammation	and	increases	parasitaemia	by	
reducing	spleen-mediated	clearance	of	the	parasite.	This	adhesion	is	mediated	by	PfEMP1,	a	
multi-variant	family	of	around	60	proteins	per	parasite	genome	which	interact	with	specific	
host	receptors.	One	of	the	most	common	of	these	receptors	is	intracellular	adhesion	
molecule-1	(ICAM-1)	which	is	bound	by	two	distinct	groups	of	PfEMP1,	A-type	and	B	or	C	
(BC)	-	type.	Here	we	present	the	first	structure	of	a	domain	from	a	B-type	PfEMP1	bound	to	
ICAM-1,	revealing	a	complex	binding	site.	Comparison	with	the	existing	structure	of	an	A-
type	PfEMP1	bound	to	ICAM-1	shows	that	the	two	complexes	share	a	globally	similar	
architecture.	However,	while	the	A-type	PfEMP1	bind	ICAM-1	through	a	highly	conserved	
binding	surface,	the	BC-type	PfEMP1	use	a	binding	site	that	is	more	diverse	in	sequence,	
similar	to	how	PfEMP1	interact	with	other	human	receptors.	We	also	show	that	A-	and	BC-
type	PfEMP1	present	ICAM-1	at	different	angles,	perhaps	influencing	the	ability	of	
neighbouring	PfEMP1	domains	to	bind	additional	receptors.	This	illustrates	the	deep	
diversity	of	the	PfEMP1	and	demonstrates	how	variations	in	a	single	domain	architecture	
can	modulate	binding	to	a	specific	ligand	to	control	function	and	facilitate	immune	evasion.	
	
Significance	statement:		
Malaria	is	one	of	the	deadliest	infectious	diseases	to	affect	humans,	causing	over	two	
hundred	million	cases	and	hundreds	of	thousands	of	deaths	annually.	Its	fatal	symptoms	
occur	when	parasites	cause	infected	human	red	blood	cells	to	stick	to	human	tissue	
surfaces,	blocking	blood	flow	and	causing	inflammation.	This	stickiness	is	caused	by	parasite	
PfEMP1	proteins,	which	interact	with	different	human	receptors,	such	as	ICAM-1.	In	this	
paper,	we	demonstrate	how	PfEMP1	proteins	bind	to	ICAM-1.	We	find	that	this	can	happen	
in	two	different	but	related	ways,	perhaps	influencing	which	additional	receptors	PfEMP1	
can	bind.	We	show	how	the	parasite	can	adapt	to	allow	it	to	stick	tightly	while	reducing	the	
chance	that	it	is	detected	and	destroyed.	
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Introduction:	
Despite	ongoing	efforts	to	reduce	global	disease	burden,	malaria	is	still	one	of	the	world’s	
most	prominent	diseases,	with	an	estimated	219	million	cases	each	year	(1).	The	symptoms	
occur	as	Plasmodium	parasites	divide	within	red	blood	cells	of	infected	individuals.	
Plasmodium	falciparum,	the	cause	of	the	deadliest	form	of	human	malaria,	invades	and	
replicates	within	mature	erythrocytes.	This	intracellular	habitat	reduces	its	susceptibility	to	
detection	by	the	mammalian	immune	system,	but	makes	it	vulnerable	to	splenic	clearance.	
However,	the	parasite	also	displays	members	of	variant	protein	families	on	the	surface	of	
infected	erythrocytes,	including	the	multi-domain	Plasmodium	falciparum	erythrocyte	
membrane	proteins	1	(PfEMP1).	These	PfEMP1	cause	infected	erythrocytes	to	adhere	to	the	
surfaces	of	blood	vessels	and	tissues,	removing	them	from	circulation	and	protecting	the	
parasite	within	from	spleen-mediated	destruction	(2).	
	
PfEMP1	have	evolved	under	conflicting	selection	pressures.	On	one	hand,	they	have	
diversified	into	a	large	protein	family	to	evade	immune	clearance,	with	around	sixty	
antigenically	distinct	members	encoded	in	each	parasite	genome	(3,	4).	Since	only	a	single	
PfEMP1	is	usually	expressed	in	each	infected	erythrocyte,	this	allows	for	antigenic	switching,	
enabling	the	population	to	survive	as	cells	displaying	the	previous	PfEMP1	variant	are	
detected	and	destroyed	(5).	On	the	other	hand,	PfEMP1	have	maintained	their	capacity	to	
bind	specific	human	cell	surface	proteins,	often	allowing	them	to	continue	to	mediate	
adhesion	to	human	cell	and	tissue	surfaces	even	after	switching	to	a	different	PfEMP1	
variant.	Based	on	their	chromosomal	location,	the	majority	of	PfEMP1	are	categorised	in	
three	major	groups;	A,	B	and	C	(6,	7).	Depending	on	the	receptor	to	which	they	bind,	
expression	of	certain	groups	of	PfEMP1	correlate	with	different	symptoms	and	final	
outcomes	of	malaria	episodes,	with	group	A	PfEMP1	associated	with	severe	malaria,	while	
the	other	groups	tend	to	be	linked	with	mild	malaria,	although	the	situation	is	less	clear	for	
group	B	PfEMP1	(8–10).		
	
PfEMP1	bind	to	a	variety	of	human	ligands	(11,	12),	the	most	common	of	which	are	cluster	
of	differentiation	36	(CD36),	endothelial	protein	C	receptor	(EPCR)	and	intercellular	
adhesion	molecule	1	(ICAM-1)	(13–15).	Group	B	and	C	(BC)	PfEMP1	that	contain	cysteine-
rich	inter-domain	region	(CIDR)a2-6	domains	bind	to	CD36	and	are	associated	with	
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parasites	which	cause	mild	or	uncomplicated	malaria	(16,	17),	while	the	A-type	PfEMP1	that	
contain	CIDRa1	domains	that	bind	to	EPCR	are	associated	with	severe	childhood	malaria	
(14,	18–21).	However,	finding	a	correlation	between	expression	of	PfEMP1	that	bind	to	
ICAM-1	and	malaria	outcome	has	been	much	more	challenging,	with	conflicting	results	
about	whether	ICAM-1	binding	is	linked	to	cerebral	malaria	(22–25).	ICAM-1	binding	is	
mediated	by	a	subset	of	Duffy	binding-like	(DBL)	domains,	the	DBLb	domains,	which	are	
found	in	either	A-type	or	BC-type	PfEMP1	(26–29).	Recent	studies	showed	that	A-type	
PfEMP1	with	an	ICAM-1	binding	DBLb	domain	also	contain	a	neighbouring	EPCR-binding	
CIDRa	domain	and	that	these	dual-binding	PfEMP1	are	associated	with	cerebral	malaria	(22,	
30,	31).	No	such	correlation	has	been	made	for	BC-type	PfEMP1	containing	a	DBLb domain.	
	
Structural	studies	have	given	significant	insight	into	diversity	and	conservation	of	receptor	
binding	sites	in	PfEMP1.	Mapping	sequence	diversity	for	EPCR-binding	CIDRa	domains	onto	
the	structure	of	a	CIDRa1	domain	bound	to	EPCR	reveals	that	while	the	EPCR	binding	
surfaces	are	highly	diverse	in	sequence,	they	retain	a	specific	shape	and	overall	chemical	
properties	(18).	This	allows	conservation	of	ligand	binding	despite	sequence	diversification.	
This	is	similar	to	the	CD36-binding	CIDRa	domains,	where	the	shape	and	chemistry	of	the	
binding	site	are	conserved	despite	extensive	sequence	diversity	(16).	In	contrast,	a	similar	
analysis	shows	that	DBLb domains	from	A-type	ICAM-1	binding	PfEMP1	are	significantly	less	
diverse.	Instead,	they	contain	a	sequence	motif	which	shows	nearly	total	conservation	in	
residues	which	directly	contact	ICAM-1,	or	that	are	responsible	for	the	correct	fold	of	the	
ICAM-1	binding	site.	However,	this	sequence	motif	is	absent	in	DBLb domains from	B-	or	C-
type	PfEMP1	that	bind	ICAM-1	(22).	To	understand	how	these	BC-type	PfEMP1	interact	with	
ICAM-1,	we	have	determined	the	structure	of	the	DBLb	domain	of	the	B-type	IT4var13	
PfEMP1	in	complex	with	the	N-terminal	domains	of	ICAM-1,	revealing	divergent,	but	similar	
modes	of	ICAM-1	binding	across	the	PfEMP1.	
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Results:	
	
ICAM-1	binding	domains	from	BC-type	and	A-type	PfEMP1	are	evolutionary	distinct		
We	first	performed	an	updated	phylogenetic	analysis	of	all	DBLb	domains	that	have	been	
tested	for	the	ability	to	bind	to	ICAM-1	(Table	S1).	Since	publication	of	similar	analyses,	in	
which	the	only	available	B-	and	C-type	PfEMP1	sequences	were	from	the	IT4	strain	of	
Plasmodium	falciparum	(22,	26,	28),	three	ICAM-1	binding	DBLb	domains	from	non-IT4	
group	B	and	C	PfEMP1	have	been	identified	(27).	Inclusion	of	these	sequences	confirmed	
the	clustering	of	A-type	ICAM-1	binding	domains	observed	earlier,	and	showed	that	ICAM-1	
binding	domains	from	group	B	and	C	PfEMP1	mostly	form	a	separate,	albeit	less	well-
defined	cluster	(Fig.	1A).	This	clustering	is	particularly	prominent	in	the	region	of	the	
sequence	which	corresponds	to	the	ICAM-1	binding	site	of	the	A-type	DBLb	domains,	with	
BC-type	DBLb	domains	lacking	all	of	the	essential	features	of	the	A-type	binding	site	(Fig.	
1B).	An	exception	to	this	is	the	DBLb	domain	of	the	B-type	PfEMP1	IT4var31,	which	contains	
many	of	the	key	features	of	the	conserved	A-type	ICAM-1	binding	site,	but	differs	from	the	
consensus	sequence	at	crucial	isoleucine	and	proline	residues	(I1078	and	P1116)	(Fig.	1B).	
This	suggests	that	IT4var31	is	either	an	A-type	PfEMP1	that	has	diverged	in	this	region,	or	is	
an	intermediate	between	A-type	and	BC-type	PfEMP1.		With	this	exception,	the	differences	
between	ICAM-1	binding	DBLb	domains	indicate	that	A-type	and	BC-type	PfEMP1	vary	in	
their	ICAM-1	binding	sites	and	potentially	also	differ	in	their	engagement	of	the	receptor.	
	
The	structural	basis	for	ICAM-1	binding	by	BC-type	PfEMP1	
To	understand	these	differences	in	ICAM-1	binding	and	to	allow	comparison	with	the	
previous	structure	of	an	A-type	ICAM-1	binding	DBLb	domain,	we	aimed	to	structurally	
characterise	a	BC-type	PfEMP1	DBLb	domain	bound	to	ICAM-1.	We	purified	a	diverse	set	of	
DBLb	domains,	either	alone	or	bound	to	the	two	N-terminal	domains	of	ICAM-1	(ICAM-
1D1D2)	and	conducted	crystallisation	trials.	To	remove	any	flexible	regions	that	might	hinder	
crystallisation,	we	added	proteases	to	the	crystallisation	drops.	The	DBLb	domain	from	
IT4var13	formed	crystals	which	diffracted	to	2.17	Å	resolution	(Table	1).	We	determined	its	
structure	by	molecular	replacement,	using	a	truncated	version	of	the	PF11_0521	DBLb	
domain	(Plasmo	DB:	PF3D7_1150400)	as	a	search	model	(PDB:	5MZA)	(22).	A	complex	of	the	
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same	domain	bound	to	ICAM-1D1D2	formed	crystals	in	the	presence	of	carboxypeptidase	B	
and	these	diffracted	to	3.67	Å	resolution	(Table	1),	allowing	structure	determination	using	a	
known	structure	of	ICAM-1D1D2	(PDB:	1IC1)	(32)	and	a	pruned	version	of	the	final	structure	
of	the	IT4var13	DBLb	domain	as	molecular	replacement	search	models.		
	
The	IT4var13	DBLb	domain	adopts	the	classical	DBL	domain	fold	(33),	consisting	of	an	a-
helical	core	decorated	by	extensive	loops	(Fig.	S1A).	Comparison	of	the	unbound	and	the	
ICAM-1D1D2-bound	DBLb	domains	showed	little	variation	in	structure	upon	ligand	binding	
(root	mean	square	deviation	of	1.07	Å	over	backbone	Ca)	with	variation	predominantly	
located	in	loops	(residues	805-809,	833-840	and	1107-	1117)	(Fig.	S1B).		
	
The	IT4var13	DBLb	domain	interacts	with	domain	1	and	2	of	ICAM-1	through	a	complex	
binding	site,	the	location	of	which	is	compatible	with	a	previous	study	(28),	and	binding	is	
mediated	by	three	types	of	interaction	(Fig.	2,	Fig.	S1C,	Table	S2).	A	major	part	of	the	
interface	is	mediated	by	hydrogen	bonds,	contributed	by	DBLb domain	side	chains	from	a	
central	loop	(residues	973-976)	and	helices	in	the	C-terminal	third	(subdomain	3)	of	the	
domain	(residues	1098-1121)	(Fig.	2A).	All	of	these	DBLb	sidechains	target	the	backbone	of	
ICAM-1,	with	the	exception	of	glutamate	1098,	which	forms	hydrogen	bonds	with	arginine	
49	in	ICAM-1D1.	Secondly,	a	loop	from	the	DBLb	domain	(residues	1107-1117)	interacts	
through	backbone-backbone	hydrogen	bonds	with	ICAM-1D1	to	add	an	antiparallel	b-strand	
to	the	A’GFC	b-sheet	of	ICAM-1D1	(Fig.	2B).	Such	b-strand	augmentation	is	a	common	motif	
in	protein-protein	interactions	(34),	but	has	not	been	observed	in	other	PfEMP1-receptor	
interactions.	In	the	unbound	DBLb	domain,	this	loop	adopts	a	different	conformation	which	
is	stabilised	through	crystal	contacts	(Fig.	1B,	Fig.	S1D),	indicating	that	it	is	flexible	and	
becomes	stabilised	upon	interaction	with	ICAM-1.	This	is	analogous	to	a	different	
intrinsically	disordered	loop	that	becomes	ordered	to	form	part	of	the	ICAM-1	binding	site	
of	A-type	PfEMP1	(22).	Finally,	the	interface	is	stabilised	by	a	cluster	of	hydrophobic	
residues	found	on	an	elongated	helix	of	the	DBLb	domain	and	two	subsequent	loops	
(residues	1102-1139)	(Fig.	2C).	This	cluster	complements	a	hydrophobic	patch	on	ICAM-1D1	
which	has	previously	been	identified	as	important	for	ICAM-1	binding	by	B-type	PfEMP1	(27,	
35,	36).		
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Limited	sequence	conservation	of	the	BC-type	ICAM-1	binding	site		
We	next	assessed	the	role	of	different	residues	for	binding	of	the	IT4var13	DBLb	domain	to	
ICAM-1	by	surface	plasmon	resonance	(SPR).	Since	the	interaction	involves	a	flexible	loop	
that	becomes	ordered	upon	ICAM-1	binding,	we	first	used	an	SPR	based	assay	to	determine	
if	the	binding	event	involves	a	time-dependent	conformational	rearrangement.	In	such	a	
case,	the	amount	of	stable	complex	formed	can	depend	on	the	association	time,	with	longer	
association	times	required	to	allow	the	second	step	of	a	two-step	binding	process	to	take	
place,	resulting	in	larger	quantities	of	stable	complex	and	slower	dissociation	rates	(37).	
Indeed,	the	binding	of	IT4var13	DBLb	to	ICAM-1	showed	such	behaviour,	with	the	
dissociation	rate	decreasing	with	an	increase	in	association	time,	suggesting	reordering	of	
components	of	the	binding	site	(Fig.	S2).	For	this	reason,	we	fitted	subsequent	SPR	data	to	a	
two-state	binding	model	which	better	describes	such	interactions	involving	a	
conformational	change,	determining	an	affinity	of	1.22nM	for	IT4var13	DBLb	to	ICAM-1	(Fig.	
3,	Table	S3).	
	
We	next	analyzed	through	mutagenesis	which	features	of	the	binding	site	are	essential	for	
interaction	with	ICAM-1,	aiming	to	identify	conserved	markers	of	ICAM-1	binding	among	BC-
type	DBLb domains.	We	mutated	each	of	the	sidechains	in	the	IT4var13	DBLb	domain	that	
directly	contact	ICAM-1	through	hydrogen	bonds	or	non-polar	interactions	and	tested	them	
for	binding	to	ICAM-1D1D5-Fc	by	SPR	(Fig.	3).	We	found	that	only	one	(Q1103)	of	the	five	
sidechains	that	hydrogen	bond	with	ICAM-1	plays	a	major	role	in	binding,	with	the	Q1103A	
mutation	causing	a	200-fold	decrease	in	affinity	(Fig	3,	Table	S3).	In	contrast,	mutation	of	
three	of	the	four	hydrophobic	residues	that	contact	ICAM-1	(L1102,	I1106	and	F1113)	
reduce	the	interaction	affinity	by	more	than	200-fold	(Fig.	3,	Table	S3),	highlighting	the	
importance	of	this	hydrophobic	patch	for	ICAM-1	binding.	None	of	these	mutations	
disrupted	the	structure	of	the	DBLb	domain,	as	determined	by	CD	spectroscopy	and	thermal	
melt	experiments	(Fig.	S3).	We	also	mutated	three	glycines	that	form	part	of	the	loop	that	
interacts	with	ICAM-1	by	b-strand	augmentation	to	test	whether	they	confer	flexibility	that	
allows	the	loop	to	adopt	its	bound	conformation, but	these	mutations	did	not	affect	the	
interaction	(Fig.	3,	Table	S3).		
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To	determine	whether	these	binding	properties	are	conserved,	we	analysed	the	degree	of	
conservation	of	the	interacting	residues	among	the	known	ICAM-1	binding	DBLb	domains	
from	other	BC-type	PfEMP1,	excluding	the	outlier	IT4var31.	Sequence	alignment	revealed	
limited	conservation	in	sequence	and	chemical	properties	among	these	residues,	with	
hydrophobic	residues	exchanged	for	polar	residues	and	vice	versa	(Fig.	4A).	The	only	notable	
exception	is	phenylalanine,	F1113,	which	forms	part	of	the	hydrophobic	patch	that	binds	to	
ICAM-1	and	is	an	aromatic	or	hydrophobic	residue	in	all	domains	analysed.	Despite	the	lack	
of	sequence	identity,	we	noted	that	all	ICAM-1	binding	DBLb	domains	display	surface-
exposed	hydrophobic	and	aromatic	residues	along	the	top	third	of	the	elongated	a-helix	
that	forms	part	of	the	binding	site,	albeit	in	positions	that	vary	within	a	range	of	four	helical	
turns	(Fig.	4A	and	4B).	To	test	whether	these	residues	are	equivalent	in	function	to	the	
hydrophobic	patch	in	IT4var13,	we	introduced	mutations	into	the	DBLb	domain	of	the	C-
type	PfEMP1	J1a	(27)	and	tested	their	effect	on	binding	to	ICAM-1	by	SPR.	With	the	
exception	of	L1093D,	these	mutations	reduced	binding	and	affinity	by	2	to	20-fold,	which	
was	not	due	to	the	disruption	of	the	overall	fold	of	the	domain,	as	verified	by	CD	
spectroscopy	and	thermal	melt	experiments	(Fig.	4C,	Fig.	S4	and	Table	S4).	Of	these	
residues,	Y1115	in	J1a	is	equivalent	in	position	to	F1113	in	IT4var13	and	performs	an	
equivalently	important	role	in	binding.	Y1097	and	L1096	in	J1a	form	a	hydrophobic	patch	
which	appears	functionally	equivalent	to	the	patch	formed	by	residues	L1102	and	I1106	in	
IT4var13,	despite	being	found	in	a	different	region	of	the	sequence	and	a	different	location	
on	the	helix.	This	use	of	similar	binding	features,	contributed	by	different	regions	of	the	
domains	illustrates	significant	plasticity	in	how	the	BC-type	DBLb	bind	to	ICAM-1.	
	
The	flexible	loop	that	binds	ICAM-1	by	b-strand	augmentation	in	IT4var13	DBLb	is	also	
present	in	other	BC	type	PfEMP1	(Fig.	4A).	To	test	whether	these	use	a	similar	mechanism	of	
b-strand	addition	to	bind	ICAM-1	we	once	again	assessed	the	dependence	of	dissociation	
rate	on	association	time	(Fig.	S2).	For	each	of	the	tested	DBLb	domains	from	BC-type	
PfEMP1	(IT4var13,	J1a	and	Bc12)	the	specific	dissociation	rate	after	binding	to	ICAM-1	
decreases	with	an	increase	in	association	time,	indicating	that	the	interaction	involves	
reordering	of	components	of	the	binding	site	(Fig.	S2).	We	observe	the	same	effect	for	DBLb	
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domains	from	A-type	PfEMP1	(Pf11_0521	and	PFD1235w),	in	which	a	different	flexible	loop	
becomes	ordered	during	ICAM-1	binding	(22),	but	not	for	CIDRa	domains	(HB3var3	and	
IT4var20)		that	bind	to	their	receptor	EPCR	without	any	apparent	structural	rearrangement	
(18).		
	
While	the	flexible	loop	varies	significantly	in	length	between	B-	and	C-type	ICAM-1	binding	
DBLb	domains,	most	variants	contain	a	glycine	that	follows	the	conserved	hydrophobic	or	
aromatic	residue	(Fig.	4A).	While	these	glycine	residues	have	no	significance	for	ICAM-1	
binding	in	IT4var13	DBLb	(Fig.	3)	they	might	be	necessary	for	longer	variants	of	the	loop	to	
adopt	the	ICAM-1	bound	conformation.	To	test	this,	we	mutated	this	glycine	in	the	J1a	DBLb	
and	found	a	7-fold	reduced	binding	level	and	1.5-fold	reduced	affinity,	highlighting	the	
importance	of	flexibility	of	this	elongated	loop	(Fig.	4C).	
	
In	summary,	the	ICAM-1	binding	site	of	BC-type	PfEMP1	is	defined	by	the	overall	chemical	
nature	of	key	elements	such	as	a	surface-exposed	hydrophobic	patch	and	a	flexible	loop	
that	becomes	ordered	upon	ICAM-1	binding.	However,	the	position,	sequence	and	length	of	
these	elements	vary	significantly,	in	stark	contrast	to	the	highly	conserved	binding	site	of	A-
type	PfEMP1.		
	
Comparison	of	ICAM-1	binding	by	DBLb	domains	from	A-	and	BC-type	PfEMP1	
Phylogenetic	analyses	of	ICAM-1	binding	DBLb	domains	(Fig	.	1)	and	the	significant	variation	
in	sequence	conservation	between	the	binding	sites	from	A-type	and	BC-type	PfEMP1	(Fig.	
5A)	suggests	that	two	variants	of	ICAM-1	binding	sites	have	evolved	and	exist	in	parallel,	a	
property	so	far	unique	among	PfEMP1-receptor	interactions.	We	therefore	asked	what	the	
specific	differences	between	these	two	types	of	binding	sites	are	and	whether	these	would	
have	any	functional	consequences	for	ICAM-1	binding.	
	
The	A-type	PfEMP1	PF11_0521	and	the	B-type	PfEMP1	IT4var13	have	ICAM-1	binding	sites	
in	similar	locations.	However,	the	B-type	binding	site	is	more	compact	and	the	overall	
structure	of	the	DBLb	domain	in	this	region	is	more	similar	to	that	of	previously	
characterised	non-ICAM-1	binding	domains	(Fig.	5B	and	Fig.	S5)	(38).	In	contrast,	the	A-type	
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binding	site	protrudes	from	this	framework	through	an	elongated	a-helix	and	a	loop	that,	in	
the	ICAM-1	bound	conformation,	project	away	from	the	domain.	Interestingly,	this	also	
results	in	a	different	binding	angle	for	ICAM-1	for	these	two	domain	types.	An	overlay	of	the	
two	structures,	based	on	the	DBLb domain,	shows	that	while	domain	1	of	ICAM-1	is	in	a	
similar	position	in	both	structures,	the	protruding	A-type	ICAM-1	binding	site	fixes	the	C-
terminus	of	domain	2	at	an	angle	that	is	~30O	different	from	the	position	that	it	adopts,	
relative	to	the	DBLb domain,	when	bound	to	the	B-type	IT4var13	(Fig.	5C).	
	
To	test	whether	this	difference	in	angle	is	a	general	property	of	A-	and	BC-type	PfEMP1,	we	
produced	two	additional	ICAM-1	binding	DBLb	domains	from	each	of	the	A-type	(PFD1235w	
and	KF984156)	and	BC-type	(Bc12a	and	J1a)	PfEMP1.	We	then	collected	solution	small	angle	
x-ray	scattering	(SAXS)	data	for	all	six	domains,	either	alone	or	in	complex	with	ICAM-1D1D2	
(Table	S5)	and	used	these	data	to	guide	molecular	docking	experiments,	with	the	crystal	
structures	of	ICAM-1D1D2,	the	PF11_0521	and	IT4var13	DBLb	domain	structures	and	
homology	models	of	the	other	domains	as	input	for	HADDOCK	(39,	40).	The	models	of	the	
DBLb	ICAM-1D1D2	complexes	obtained	after	SAXS	filtering	(Fig.	S6A)	show	that	this	method	
reproduces	the	complexes	observed	in	the	crystal	structures	with	high	precision	(root	mean	
square	deviation	over	backbone	Ca	of	0.83	Å	for	PF11_0521	DBLb-ICAMD1D2	and	1.47	Å	for	
IT4var13	DBLb-ICAMD1D2)	(Fig.	S6B).	More	importantly,	it	shows	that	the	resulting	models	fit	
into	two	distinct	classes	with	respect	to	the	ICAM-1	angle,	with	all	of	the	A-type	DBLb	
domains	in	the	same	class	as	PF11_0521	while	the	BC-type	DBLb	domains	group	with	
IT4var13	(Fig.	5D	and	E).	Ab	initio	envelopes	calculated	from	the	SAXS	data	further	support	
this	observation	and	indicate	that	the	differences	are	not	due	to	significantly	different	
shapes	of	the	DBLb	domains	themselves	(Fig.	S7).	Taken	together,	these	data	show	that	the	
structural	variations	between	the	two	types	of	ICAM-1	binding	site	result	in	different	
binding	angles	for	this	receptor	and	that	this	difference	is	consistent	between	A-type	and	
BC-type	PfEMP1.		
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Discussion:	
	
The	PfEMP1	DBLb	domains	that	bind	to	ICAM-1	are	unusual	in	that	they	segregate	into	two	
evolutionarily	distinct	clusters,	the	A-	and	BC-types	(Fig.	1)	(22,	26).	In	this	study	we	
compare	our	structure	of	a	BC-type	ICAM-1	binding	DBLb	domain	with	the	previously	
determined	structure	of	an	A-type	domain	(22),	revealing	that	both	contain	a	globally	
similar	ICAM-1	binding	site,	in	a	similar	location.	However,	these	two	domains	differ	in	the	
conformation	of	the	ICAM-1	binding	region,	the	degree	of	sequence	conservation	of	the	
binding	site	and	the	angle	at	which	ICAM-1	is	bound	relative	to	the	DBLb	domain.	This	raises	
the	question	of	why	the	parasite	uses	two	similar	and	yet	distinct	types	of	binding	sites	to	
interact	with	the	same	receptor.		
	
The	BC-type	DBLb	domains	and	other	PfEMP1	domains	share	the	overall	chemical	nature	of	
their	interactions	with	their	ligands.	The	core	of	their	binding	site	is	a	hydrophobic	cluster,	
which	is	complemented	by	hydrogen	bonds	contributed	by	both	side	chains	and	backbone	
groups.	These	features	are	similar	to	those	by	which	DBLb	domains	from	A-type	PfEMP1	
interact	with	ICAM-1	(22).	A	similar	picture	is	also	seen	in	CIDRa	domains	that	interact	with	
EPCR	and	CD36	(16,	18),	which	bind	their	receptors	through	hydrophobic	or	aromatic	
residues	that	either	protrude	from	the	domain	or	form	a	cavity	that	accepts	hydrophobic	
residues	from	the	receptor.	Therefore,	in	all	of	the	structurally	characterised	PfEMP1-
receptor	interactions,	a	hydrophobic	patch	lies	at	the	heart	of	the	binding	site	and	mutation	
of	these	hydrophobic	residues	has	a	major	effect	on	the	overall	affinity,	with	changes	in	
both	association	and	dissociation	rates	(Tables	S3	and	S4)	(16,	18,	22).	In	addition,	in	all	four	
cases,	adjacent	residues	mediate	hydrogen	bonds	that	stabilise	the	interaction	and	generate	
increased	surface	complementarity	with	the	receptor.	This	conservation	of	a	hydrophobic	
core,	together	with	larger	complementary	hydrophilic	surfaces,	allows	the	formation	of	
stable	PfEMP1-receptor	complexes,	enabling	infected	red	blood	cells	to	withstand	the	
forces	of	blood	flow	during	cytoadhesion	and	to	evade	splenic	clearance.		
	
Despite	these	shared	features,	there	are	significant	differences	in	the	degree	of	sequence	
conservation	between	ICAM-1	binding	sites	of	the	A-	and	BC-type	DBLb	domains.	The	
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residues	through	which	BC-type	PfEMP1	bind	to	ICAM-1	are	highly	variable	in	sequence,	and	
the	relative	positions	of	interacting	residues	and	the	length	of	the	loop	that	forms	a	b-sheet	
addition	upon	ICAM-1	binding	differ	between	domain	variants.	This	is	conceptually	similar	
to	CIDRa	domains	that	bind	EPCR	or	CD36	(16,	18),	which	also	retain	the	overall	shape	and	
the	chemistry	of	their	binding	sites,	while	at	the	same	time	diversifying	in	sequence.	In	
marked	contrast,	in	the	A-type	PfEMP1	that	bind	ICAM-1	all	residues	that	are	critical	for	
direct	interaction	with	the	receptor,	or	the	positioning	of	these	side	chains,	are	absolutely	
conserved	(22).		
	
So,	which	is	more	common,	a	binding	site	with	a	high	level	of	sequence	variation	or	one	in	
which	interacting	residues	are	conserved?	In	the	context	of	the	pressure	to	diversify	to	
maintain	the	capacity	for	immune	evasion,	theory	would	predict	the	former.	Indeed,	
PfEMP1	containing	the	highly	variable	EPCR,	CD36	and	ICAM-1	binding	sites	are	abundant	in	
the	PfEMP1	repertoire	of	parasite	genomes	from	reference	strains	or	field	isolates.	For	
example,	in	the	3D7	genome,	84%	of	PfEMP1	contain	domains	that	bind	CD36	and	11%	
contain	EPCR-binders	while,	in	the	IT4	genome,	11%	of	PfEMP1	contain	BC-type	ICAM-1	
binding	DBLb	domains	(41).	In	contrast,	A-type	ICAM-1	binding	sites	occur	at	an	average	
frequency	of	one	per	genome	(~1.3%	of	PfEMP1)	(42).	Therefore,	a	highly	conserved	binding	
site	is	the	exception	rather	than	the	rule.	
	
This	raises	the	question	of	why	the	parasite	has	evolved	and	maintained	two	similar	and	yet	
distinct	classes	of	binding	sites	to	interact	with	the	same	receptor.	In	particular,	the	highly	
conserved	A-type	ICAM-1	binding	site	would	appear	disadvantageous	under	immune	
pressure.	Indeed,	antibodies	that	block	EPCR-binding	by	CIDRa1	domains	have	very	limited	
cross-inhibitory	activity	against	other	variants	of	this	domain	(43).	In	contrast,	antibodies	
that	target	the	A-type	binding	site	can	broadly	cross-inhibit	ICAM-1	binding,	and	children	in	
malaria-endemic	regions	rapidly	acquire	such	antibodies	(22,	44–46).	A	potential	
explanation	for	retention	of	the	A-type	binding	site,	despite	it	being	the	target	of	such	a	
cross-inhibitory	immune	response,	is	that	it	confers	a	specific	advantage	compared	to	the	
more	variable	BC-type	binding	site.	Indeed,	some	studies	suggest	that	A-type	PfEMP1	are	
preferentially	expressed	in	individuals	with	limited	immunity	and	that	antibodies	against	
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these	PfEMP1	are	acquired	first	(47,	48),	indicating	that	they	can	confer	an	early	survival	
advantage	for	the	parasite.	
	
A	possible	reason	why	parasites	have	evolved	both	A-	and	BC-type	ICAM-1	binding	domains	
is	that,	while	these	domains	bind	to	ICAM-1	equally	well	(22,	27,	30,	49–51),	they	may	
differently	influence	the	ability	of	neighbouring	domains	to	bind	additional	receptors.	
Previous	studies	have	shown	that	all	PfEMP1	that	contain	a	DBLb	domain	with	an	A-type	
ICAM-1	binding	site	also	contain	an	adjacent	CIDRa1	domain	with	an	EPCR-binding	site,	and	
that	these	PfEMP1	can	bind	simultaneously	to	both	receptors	(22,	30).	Such	dual-binding	is	
not	limited	to	A-type	PfEMP1,	since	some	BC-type	PfEMP1	containing	an	ICAM-1	binding	
domain	also	have	a	CD36-binding	domain	(8,	15,	29)	and	ICAM-1	and	CD36	have	been	
shown	to	cooperate	to	enhance	the	binding	of	infected	erythrocytes	to	microvascular	cells	
(15,	52).	However,	in	A-type	PfEMP1,	dual-binding	to	ICAM-1	and	EPCR	have	been	shown	to	
specifically	enhance	binding	of	infected	erythrocytes	to	endothelial	cells	under	
physiologically	higher	shear	stresses	(22,	50),	which	offers	a	distinct	advantage	to	the	
parasite,	especially	for	cytoadherence	to	brain	endothelial	cells	where	CD36	is	absent. 
	
The	ability	of	a	PfEMP1	to	bind	simultaneously	to	two	membrane	bound	receptors	will	
depend	on	its	architecture	and	on	how	it	presents	binding	site.	The	majority	of	PfEMP1	are	
thought	to	be	rigid,	elongated	proteins	(49,	53),	constraining	the	conformation	in	which	
they	can	interact	with	two	membrane	bound	receptors	simultaneously.	As	the	distance	
between	the	host	cell	membrane	and	the	PfEMP1	binding	site	is	~66	Å	for	CD36	and	~32	Å	
for	EPCR,	it	is	tempting	to	speculate	that	the	A-type	and	BC-type	DBLb	domains	have	
evolved	to	bind	ICAM-1	at	different	angles	in	order	to	allow	the	neighbouring	CIDRa	domain	
better	to	interact	with	either	EPCR	or	CD36	at	different	heights	from	the	host	endothelial	
membrane.	Future	studies	and	structural	insights	into	full-length	PfEMP1	will	be	needed	to	
test	this	hypothesis.	
	
In	summary,	our	characterisation	of	the	ICAM-1	binding	site	of	the	BC	type	PfEMP1	supports	
the	view	that	the	majority	of	PfEMP1	utilise	a	binding	site	that	is	highly	variable	in	sequence	
but	conserved	in	shape	and	chemistry,	allowing	these	proteins	to	retain	receptor	binding	
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capacity	while	evading	immune	detection.	This	also	highlights	the	unusual	conservation	of	
the	A-type	ICAM-1	binding	site,	reinforcing	the	view	that	it	is	a	suitable	target	for	the	
development	of	anti-disease	malaria	vaccines.	
	
	
Materials	and	Methods:	
Protein	expression	and	purification	
The	constructs	for	the	PF11_0521,	PFD1235w,	KF984156,	BC12a	and	J1a	DBLb	domains	
were	described	previously	(22,	26,	27).	Constructs	comprised	the	following	amino	acids	of	
the	respective	PfEMP1:	728-1214	of	PF11_0521,	739-1221	of	PFD1235w,	546-1036	of	
KF984156,	813-1273	of	Bc12a,	739-1195	of	J1a	and	733-1202	of	IT4var13.	All	constructs	had	
an	N-terminal	hexa-histidine	tag,	followed	by	a	Tobacco	Etch	Virus	(TEV)	protease	cleavage-
site	in	the	pET15b	expression	vector.	They	were	expressed	in	Shuffle	3030	Escherichia	coli	
(New	England	Biolabs)	at	25OC	for	16h.	The	DBLb	domains	were	purified	by	affinity	
chromatography	using	nickel-nitrilotriacetic	acid	agarose	(Ni-NTA,	Qiagen),	followed	by	size	
exclusion	chromatography	using	a	HiLoad	Superdex	75	16/60	column	(GE	Healthcare).	
Mutants	of	IT4var13	and	J1a	DBLb	were	made	using	the	Quikchange	site-directed	
mutagenesis	protocol	(Agilent	Technologies)	and	expressed	and	purified	as	described	for	
wild	type	protein.		
	
Constructs	for	ICAM-1D1D5-Fc	and	His-tagged	ICAM-1D1D2	were	described	previously	(49,	54).	
ICAM-1D1D5-Fc	comprises	amino	acids	1	to	480	of	human	ICAM-1,	fused	to	the	Fc	part	of	
human	IgG	in	a	mammalian	expression	vector	(54).	ICAM-1D1D2	comprises	amino	acids	28	to	
212	of	human	ICAM-1,	fused	to	an	C-terminal	hex-histidine	tag	in	the	pHLsec	expression	
vector	(55).	All	constructs	were	transiently	expressed	as	secreted	proteins	in	HEK293F	cells	
(Life	Technologies).	For	ICAM-1D1D2,	kifunensine	(Cayman	Chemical)	was	added	to	the	
medium	during	transfection	to	a	final	concentration	of	1.5µM.	Seven	days	after	
transfection,	the	cell	culture	supernatants	were	harvested	and	sterile-filtered.	ICAMD1D2	was	
then	purified	by	affinity	chromatography	using	Ni-NTA	affinity	(Qiagen),	and	ICAM-1D1D5-Fc	
was	purified	by	affinity	chromatography	using	a	HiTrap	Protein	A	HP	column	(GE	
Healthcare).	Both	proteins	were	further	purified	by	size	exclusion	chromatography	using	a	
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HiLoad	Superdex	75	16/60	column	(GE	Healthcare).	The	HB3var	and	IT4var20	CIDRa	
domains	and	EPCR	were	produced	as	described	previously	(18).	
	
Crystallisation	
For	crystallisation,	Ni-NTA	purified	IT4var13	DBLb	was	further	purified	by	size	exclusion	
chromatography	using	a	HiLoad	Superdex	75	16/60	column	(GE	Healthcare)	into	10mM	
HEPES,	150mM	NaCl,	pH	7.2.	For	complex	formation,	IT4var13	DBLb	was	mixed	with	a	1.5-
fold	molar	excess	of	ICAM-1D1D2	and	purified	as	described	for	IT4var13	DBLb.	Fractions	
containing	pure	IT4var13	DBLb	or	IT4var13	DBLb-ICAMD1D2	complex	were	pooled	and	
concentrated	to	23	mg/ml.	Crystals	were	grown	by	vapour	diffusion	in	sitting	drops	by	
mixing	100nl	of	protein	solution	with	100nl	of	well	solution.	To	remove	flexible	loops,	
Carboxypeptidase	B	(Sigma	Aldrich),	Chymotrypsin	(Sigma	Aldrich)	or	Endoproteinase	GluC	
(New	England	Biolabs)	were	added	to	the	crystallisation	drop	in	a	100:1	(protein:protease)	
molar	ratio.	Crystals	of	IT4var13	DBLb grew	at	291	K	in	the	presence	or	absence	of	protease	
in	conditions	from	the	JCSG+	screen	(Molecular	Dimensions)	containing	0.2M	Magnesium	
chloride	hexahydrate,	0.1M	BIS-Tris	pH	5.5	and	25%	(w/v)	PEG	3350.	For	cryo-protection,	
crystals	were	transferred	into	well	solution	containing	25%	glycerol	and	were	flash-frozen	in	
liquid	nitrogen.	Crystals	of	the	IT4var13	DBLb-ICAMD1D2	complex	grew	only	in	the	presence	
of	Carboxypeptidase	B	at	291	K	in	conditions	from	the	ProPlex	screen	(Molecular	
Dimensions)	containing	0.1	M	Tris	pH	8.0	and	25%	(v/v)	PEG	350	MME.	The	crystals	were	
cryo-protected	by	transfer	into	well	solution	containing	0.1	M	Tris	pH	8.0	and	32%	(v/v)	PEG	
350	MME	and	were	flash-frozen	in	liquid	nitrogen.	
	
Data	collection,	phasing	and	refinement	
Data	for	crystals	of	IT4var13	DBLb	were	collected	at	beamline	IO4-1	(Diamond	Light	Source,	
UK)	using	x-rays	at	a	wavelength	of	0.92	Å	and	a	Pilatus	6M-F	detector	(Dectris,	Baden-
Daettwil,	Switzerland).	Data	for	crystals	of	the	IT4var13	DBLb-ICAMD1D2	complex	were	
collected	at	beamline	IO3	(Diamond	Light	Source,	UK)	using	x-rays	at	a	wavelength	of	1.0	Å	
and	an	Eiger2	X	16M	detector	(Dectris,	Baden-Daettwil,	Switzerland).	Both	datasets	were	
processed	using	the	XIA2/DIALS	pipeline	(56)	in	the	CCP4i2software	suite	(57,	58)	for	
indexing	and	scaling.		
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The	structure	of	IT4var13	DBLb was	solved	by	molecular	replacement	with	Phaser	(59)	using	
a	search	model	consisting	of	a	poly-alanine	model	of	the	PF11_0521	DBLb	domain	(PDB:	
5MZA)	(22)	in	which	helices	in	subdomain	3	were	shortened	and	all	loops	were	removed.	
Molecular	replacement	found	one	copy	of	the	search	model	in	the	asymmetric	unit	and	the	
remaining	parts	of	IT4var13	DBLb	were	built	through	iterative	cycles	of	model	building	in	
Coot	(60)	and	refinement	in	Phenix	(61).		
	
The	structure	of	the	IT4var13	DBLb-ICAMD1D2	complex	was	solved	by	molecular	replacement	
with	Phaser	using	pruned	poly-alanine	models	of	the	IT4var13	DBLb	domain	and	ICAM-1D1D2	
(PDB:	1IC1)	(32)	as	search	models.	To	allow	for	flexibility	between	domain	1	and	domain	2	of	
ICAM-1D1D2,	the	domains	were	used	as	separate	search	models.	Molecular	replacement	
found	one	copy	of	the	complex	in	the	asymmetric	unit	and	the	remaining	parts	were	built	
through	iterative	cycles	of	model	building	in	Coot	and	refinement	in	Phenix.	The	structures	
were	refined	to	final	Ramachandran	statistics	of	95.6%	residues	in	the	favoured	regions,	
4.4%	in	the	allowed	regions	and	no	residues	in	the	disallowed	regions	for	IT4var13	DBLb	and	
95.0%	residues	in	the	favoured	regions,	5.0%	in	the	allowed	regions	and	no	residues	in	the	
disallowed	regions	for	the	IT4var13	DBLb-ICAMD1D2	complex.	The	coordinate	and	structure	
factor	data	are	deposited	in	the	protein	data	bank	(PDB)	under	the	accession	codes	6S8T	
(IT4var13	DBLb)	and	6S8U	(IT4var13	DBLb-ICAMD1D2).	All	figures	showing	structures	were	
prepared	with	PyMol	(Schroedinger	LLC).	
	
Surface	plasmon	resonance	spectroscopy	(SPR)	
SPR	experiments	were	conducted	on	a	Biacore	T200	instrument	(GE	Healthcare).	All	
proteins	were	purified	by	size	exclusion	chromatography	and	only	fractions	with	>95%	
purity	were	used	for	SPR.	To	test	binding	of	DBLb	wild	type	and	mutant	proteins	to	ICAM-1,	
ICAM-1D1D5-Fc	was	immobilised	to	850	response	units	(RU)	for	IT4var13	DBLb proteins	or	
490	RU	for	J1a	DBLb	proteins,	on	a	CM5	chip	(GE	Healthcare)	pre-coupled	with	Protein	A	
(Sigma	Aldrich).	All	DBLb	proteins	were	buffer-exchanged	into	20mM	HEPES,	300mM	NaCl,	
0.005%	Tween-20,	pH	7.2	and	concentration	series	(0.9nM-250nM	for	IT4var13	DBLb,	
0.9nM-500nM	for	J1a	DBLb)	were	injected	over	the	chip	at	30µl/min,	with	240s	association	
 17 
time	and	600s	(for	IT4var13	DBLb)	or	720s	(for	J1a	DBLb)	dissociation	time.	After	each	run,	
the	chip	was	regenerated	by	injecting	10mM	Glycine	pH	1.7	for	120s	at	10µl/min.		
	
To	test	the	effect	of	association	time	on	dissociation	rate,	ICAM-1D1D5-Fc	was	immobilised	to	
490	RU	on	a	CM5	as	described	above,	and	biotinylated	EPCR	was	immobilised	to	340	RU	on	
a	CAP	chip	using	the	Biotin	Capture	Kit	(GE	Healthcare).	DBLb	or	CIDRa	domains	were	then	
injected	over	the	chip	at	a	fixed	concentration	of	3µM	for	60s,	120s,	180s	or	240s	with	a	
dissociation	time	of	300s.	After	each	run,	the	chip	was	regenerated	by	injecting	CAPture	Kit	
regeneration	solution	(GE	Healthcare)	(for	CIDRa	binding	to	EPCR)	or	10mM	Glycine	pH	1.7	
(for	DBLb	binding	to	ICAM-1)	for	120s	at	10µl/min.	
	
All	data	were	analysed	using	the	BIAevaluation	software	2.0.3	(GE	Healthcare).	Kinetic	
values	were	determined	by	globally	fitting	the	curves	into	a	two-state	reaction	model.	All	
SPR	experiments	were	performed	in	duplicates,	and	curves	shown	are	representatives	of	
these	measurements.	
	
Size	exclusion	chromatography	coupled	small	angle	x-ray	scattering	(SEC-SAXS)	
All	SEC-SAXS	experiments	were	carried	out	at	the	B21	beamline	(Diamond	Light	Source,	UK),	
using	x-rays	at	a	wavelength	of	0.99 Å	and	an	Eiger	4M	detector	(Dectris,	Baden-Daettwil,	
Switzerland)	with	a	detector-sample	distance	of	4.014	m.	For	data	collection,	samples	were	
concentrated	and	injected	at	20OC	over	a	Superdex	200	Increase	3.2/300	column	
equilibrated	with	20mM	HEPES,	150mM	NaCl,	pH	7.2,	with	2s	exposure	for	each	frame.	The	
data	were	processed	using	the	ScÅtter	(62)	and	ATSAS	(63)	software	suites,	and	buffer	
frames	were	averaged	and	subtracted	from	averaged	frames	corresponding	to	peak	
fractions.	The	radius	of	gyration	(Rg)	was	calculated	by	Guinier	analysis	using	AutoRg	in	
PRIMUS	(64).	The	distance	distribution	function	P(r)	and	the	maximum	particle	diameter	
Dmax	were	determined	using	GNOM	(65).	To	generate	volumetric	representations	of	
envelopes,	20	ab	initio	bead	models	were	generated	using	DAMMIF	(66).	These	models	
were	than	averaged	with	DAMAVER	(67)	followed	by	refinement	against	the	original	data	
using	DAMMIN	(68).	The	resulting	bead	models	were	then	used	to	calculate	envelopes	with	
Situs.	Crystal	structures	of	the	PF11_0521	and	IT4var13	DBLb	domains,	either	alone	or	in	
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complex	with	ICAM-1D1D2,	as	well	as	models	of	the	other	DBLb domains,	alone	or	in	complex	
with	ICAM-1D1D2,	were	fitted	into	the	envelopes	using	Chimera	(69).	All	figures	showing	
envelopes	were	made	with	PyMol	(Schroedinger	LLC).	
	
Circular	dichroism	(CD)	spectroscopy	
All	CD	spectra	were	recorded	on	a	J-815	Spectropolarimeter	(Jasco),	connected	to	a	Peltier	
temperature	control	unit.	All	samples	were	dialysed	against	100mM	sodium	phosphate	
buffer,	200mM	NaF,	pH	7.2	and	adjusted	to	0.3	mg/ml.	CD	spectra	were	recorded	at	20OC	
using	a	cell	with	a	path	length	of	1mM	at	wavelengths	between	195	nm	and	250	nm	and	
spectra	recorded	for	buffer	were	subtracted	from	these	measurements.	For	thermal	melt	
experiments,	spectra	were	recorded	between	200	nm	and	250	nm,	and	between	each	
measurement,	the	temperature	was	increased	by	0.5OC	increments.		
	
Molecular	modelling	and	docking	experiments	
Homology	models	of	DBLb	domains	used	for	molecular	docking	experiments	were	
generated	with	SwissModel	(70),	using	structures	of	the	ICAM-1	bound	form	of	PF11_0521	
DBLb	(for	KF984156	DBLb	and	PFD1235w	DBLb)	or	IT4var13	DBLb	(for	Bc12a	DBLb	and	J1a	
DBLb)	as	templates.	To	assemble	complexes	of	DBLb domain	and	ICAM-1D1D2	by	molecular	
docking,	HADDOCK	(39)	was	used.	For	this,	the	structures	or	models	of	the	DBLb	domains	
and	ICAM-1D1D2	were	used	as	input	for	the	HADDOCK	web	server.	DBLb	residues	identified	
to	be	critical	for	interaction	of	A-type	PfEMP1	(22)	or	BC-type	PfEMP1	(this	study)	with	
ICAM-1,	and	ICAM-1	residues	known	to	be	important	for	the	PfEMP1-ICAM	interaction	(22,	
27),	were	defined	as	active	residues,	while	passive	residues	were	chosen	automatically.	
Other	parameters	were	as	default.	Models	from	each	docking	experiment	were	filtered	
against	solution	scattering	data	from	SEC-SAXS,	as	described	by	Karaca	et	al.	(40)	and	the	
top	scoring	model	was	selected	as	the	final	docked	complex.	
	
Phylogenetic	analysis	
For	phylogenetic	analysis	of	ICAM-1	binding	and	non-binding	DBLb	domains,	59	sequences	
of	DBLb	domains	with	known	ICAM-1	binding	phenotype	(Table	S1)	were	aligned	using	
MUSCLE	(71).	The	evolutionary	history	was	inferred	using	the	Maximum	Likelihood	method	
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based	on	the	Whelan	And	Goldman	+	Freq.	model	(72)	using	Mega	7	(73).	The	tree	with	the	
highest	log	likelihood	(-25861.52)	is	shown.	The	percentage	of	trees	in	which	the	associated	
taxa	clustered	together	is	shown	next	to	the	branches.	Initial	tree(s)	for	the	heuristic	search	
were	obtained	automatically	by	applying	Neighbor-Join	and	BioNJ	algorithms	to	a	matrix	of	
pairwise	distances	estimated	using	a	JTT	model,	and	then	selecting	the	topology	with	
superior	log	likelihood	value.	A	discrete	Gamma	distribution	was	used	to	model	evolutionary	
rate	differences	among	sites	(5	categories;	+G,	parameter	=	1.1732).	The	rate	variation	
model	allowed	for	some	sites	to	be	evolutionarily	invariable	([+I],	14.79%	sites).	The	tree	is	
drawn	to	scale,	with	branch	lengths	measured	in	the	number	of	substitutions	per	site.	All	
positions	with	less	than	95%	site	coverage	were	eliminated.	That	is,	fewer	than	5%	
alignment	gaps,	missing	data,	and	ambiguous	bases	were	allowed	at	any	position.	There	
were	360	positions	in	the	final	dataset.	The	tree	was	visualised	using	FigTree	Version	1.4.3.	
A	sequence	logo	for	residues	involved	in	ICAM-1	binding	by	A-type	or	BC-type	PfEMP1	was	
generated	using	WebLogo	3	(74),	based	on	145	protein	sequences	containing	the	A-type	
ICAM-1	binding	motif	(22)	or	10	sequences	of	BC-type	PfEMP1	known	to	bind	ICAM-1	(27,	
29,	75).	
	
Data	availability	
Data	for	the	structures	reported	here	have	been	deposited	in	the	PDB	under	the	accession	
codes	6S8T	and	6S8U.	Additional	data	supporting	the	findings	reported	in	this	manuscript	
are	available	from	the	corresponding	author	on	request.	
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Figures	and	Tables:	
	
	
	
Figure	1	–	Group	A	and	group	BC	PfEMP1	do	not	share	a	conserved	ICAM-1	binding	site		
(A)	Maximum	likelihood	tree	based	on	59	DBLb	domain	sequences.	The	tree	is	drawn	to	scale,	
with	 branch	 lengths	 measured	 in	 the	 number	 of	 substitutions	 per	 site.	 Numbers	 on	 the	
branches	 show	 bootstrap	 values.	 DBLb	 domains	 from	 A-type	 ICAM-1	 binding	 PfEMP1	 are	
highlighted	in	yellow,	DBLb	domains	from	BC-type	ICAM-1	binding	PfEMP1	in	green	and	DBLb 	
domains	shown	not	to	bind	to	ICAM-1	are	in	black	(see	also	Table	S1).	(B)	Multiple	sequence	
alignment	of	DBLb	 domains	 from	 ICAM-1	binding	PfEMP1.	Numbers	 show	positions	 in	 the	
PF11_0521	DBLb domain.	The	box	highlights	the	A-type	ICAM-1	binding	site.	Yellow	triangles	
are	residues	critical	for	direct	interaction	of	A-type	PfEMP1	with	ICAM-1.	Blue	triangles	are	
residues	important	for	the	conformation	of	the	A-type	ICAM-1	binding	site.	
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Figure	2.	The	structural	basis	for	ICAM-1	binding	by	group	B	PfEMP1	
Front	views	of	the	DBLb	domain	of	IT4var13	(green)	bound	to	ICAM-1D1D2	(D1	light	blue,	D2	
dark	 blue).	 Dashed	 boxes	 highlight	 the	 sites	 that	 contact	 ICAM-1	 through	 (A)	 side-chain	
mediated	hydrogen	bonds	or	 (B)	a	b-sheet	augmentation.	A	 third	dashed	box	compares	a	
region	of	the	ICAM-1-bound	and	unbound	conformations	of	the	IT4var13	DBLb domain.	(C)	
Back	view	of	the	IT4var13	DBLb-ICAM-1D1D2	complex.	The	dashed	box	highlights	the	site	of	
hydrophobic	contacts	between	the	DBLb	domain	and	ICAM-1D1D2	and	the	residues	in	the	DBLb	
domain	that	contact	a	hydrophobic	patch	on	the	surface	of	ICAM-1D1	(dark	yellow).	
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Figure	3	–	Mutational	analysis	of	the	ICAM-1	binding	site	from	group	B	PfEMP1	
The	different	sites	of	contact	between	the	 IT4var13	DBLb	domain	and	ICAM-1D1D2	and	the	
residues	 involved	 in	 the	binding	 site	are	 shown.	For	SPR	measurements,	 two-fold	dilution	
series	from	250nM	to	0.9nM	of	wild	type	or	mutant	IT4var13	DBLb	were	injected	over	ICAM-
1D1D5-Fc	immobilized	on	a	Protein	A	sensor	chip.	Sensorgrams	show	the	data	(black	lines)	and	
the	fit	of	a	two-state	reaction	model	(red	lines).	 	
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Figure	4	–	Limited	conservation	of	the	ICAM-1	binding	site	among	group	BC	PfEMP1		
(A)	Multiple	sequence	alignment	of	DBLb	domains	known	to	bind	ICAM-1.	Numbers	indicate	
positions	 in	 the	 IT4var13	 DBLb	 domain.	 Residues	 critical	 for	 the	 IT4var13	 DBLb-ICAM-1	
interaction	 are	 marked	 with	 red	 triangles	 while	 those	 critical	 for	 ICAM-1	 binding	 by	 J1a	
DBLb are	marked	with	 green	 triangles.	A	half	 green	and	half	 red	 triangle	marks	 a	 residue	
important	for	both	IT4var13	and	J1a	DBLb to	bind	ICAM-1.	The	flexible	loop	is	indicated	with	
a	dashed	red	box.	Surface-exposed	hydrophobic	and	aromatic	residues	along	the	helix	that	
forms	part	of	the	ICAM-1	binding	site	are	highlighted	in	yellow.	(B)	Positions	of	hydrophobic	
and	aromatic	residues	in	the	ICAM-1	binding	site	of	IT4var13	DBLb	and	equivalent	positions	
in	a	homology	model	of	the	J1a	DBLb	domain.	(C)	Binding	of	J1a	DBLb	domain	and	its	mutants	
to	ICAM-1.	Wild	type	and	mutants	were	injected	in	a	two-fold	dilution	series	from	500nM	to	
0.9	M	over	ICAM-1D1D5-Fc	immobilized	on	a	Protein	A	sensor	chip.	Sensorgrams	show	the	data	
(black	lines)	and	the	fit	of	a	two-state	reaction	model	(red	lines).	
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Figure	5	–	A-type	and	BC-type	PfEMP1	bind	ICAM-1	at	different	angles		
(A)	Sequence	alignment	of	PF11_0521,	IT4var13	and	J1a	DBLb based	on	the	alignment	shown	
in	Figure	1	and	4.	The	residues	shown	by	mutagenesis	to	be	important	for	ICAM-1	binding	are	
marked	by	triangles.	Red	triangles	mark	residues	important	in	IT4var13,	green	in	J1a,	half	red	
and	half	green	in	both	IT4var13	and	J1a,	yellow	to	interact	with	ICAM-1	in	PF11_0521	and	blue	
to	 stabilise	 the	 structure	 of	 the	 binding	 site	 in	 PF11_0521.	 (B)	 Sequence	 logo	 showing	 all	
residues	involved	in	ICAM-1	binding	of	A-	or	BC-type	PfEMP1,	based	on	10	BC-type	or	145	A-
type	DBLb	domains	known	or	predicted	to	bind	ICAM-1.	Numbering	is	based	on	the	IT4var13	
and	PF11_0521	sequences.	Red	triangles	mark	residues	of	IT4var13	that	directly	interact	with	
ICAM-1.	Yellow	triangles	mark	residues	of	PF11_0521	that	directly	interact	with	ICAM-1.	Blue	
triangles	 mark	 residues	 important	 for	 the	 conformation	 of	 the	 ICAM-1	 binding	 site	 in	
PF11_0521.	 (C)	Superposition	of	 the	DBLb	 domains	 from	PF11_0521	and	 IT4var13	 in	 their	
ICAM-1	bound	 conformation.	 The	 ICAM-1	binding	 sites	 for	PF11_0521	 (pink)	 and	 IT4var13	
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(red)	DBLb	are	indicated.	The	inset	shows	a	magnification	of	the	ICAM-1	binding	sites	of	the	
individual	 domains.	 (D)	 Overlay	 of	 the	 ICAM-1	 bound	 complexes	 of	 IT4var13	 DBLb	 and	
PF11_0521	 DBLb,	 with	 the	 DBLb	 domains	 superimposed.	 The	 C-terminus	 of	 ICAM-1D1D2	 is	
indicated.	(E)	Models	for	complexes	of	three	DBLb	domains	from	A-type	PFEMP1	or	BC-type	
PfEMP1	bound	to	ICAM-1,	superimposed	on	the	DBLb domain.	The	models	were	derived	from	
docking	 with	 HADDOCK,	 followed	 by	 filtering	 using	 SEC-SAXS	 data.	 (F)	 Schematic	
representation	of	the	overall	binding	angles	between	ICAM-1	and	DBLb	domains	from	A-type	
(red)	and	BC-type	(blue)	PfEMP1.		 	
 33 
Table	1	–	Crystallographic	data	collection	and	refinement	statistics	
	 	
	 IT4var13	DBLb		 IT4var13	DBLb-ICAM-1D1D2		
Data	Collection	 	 	
Space	group	 P1211	 P6522	
Unit	cell	parameters		
							a,	b,	c		[Å]	
							a, b, g	[O]	
	
67.3,	43.4,	87.1	
90.0,	103.6,	90.0	
	
142.4,	142.4,	224.2	
90.0,	90.0,	120.0	
Resolution	[Å]	 32.61	-	2.17	(2.21	-	2.17)	 112.11	-	3.67	(3.73	-	3.67)	
Rmerge	 0.12	(1.55)		 0.24	(1.88)	
Rpim	 0.07	(0.92)		 0.08	(0.63)	
I/sigI	 5.30	(1.56)	 6.50	(1.02)	
CC1/2	 0.99	(0.30)	 0.98	(0.55)	
Completeness	[%]	 99.81	(96.85)		 100	(100)	
Redundancy	 4.34	(4.35)	 9.83	(9.34)	
Wilson	B	Factor	(Å2)	 40.58	 124.80	
No.	of	unique	reflections	 26322	(1229)	
	
15394	(758)	
Refinement	 	 	
	
Rwork/Rfree	
	
19.96	/	22.85	
	
24.03	/	28.65	
No.	atoms	 	 	
				Protein	 3600	 4899	
				Ligand	 -	 56	
				Water	 122	 -	
B-Factors	(Å2)	 	 	
				Protein	 62.85	 160.02	
				Ligand	 -	 215.66	
				Water	 48.81	 -	
R.m.s.	deviations	 	 	
					Bond	lengths	[Å]	 0.003	 0.003	
					Bond	angles	[O]	 0.457	 0.701	
	 	 	
Values	in	parentheses	are	for	the	highest	resolution	shell.	
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Fig.	 S1	 –	 Comparison	 of	 the	 structure	 of	 IT4var13	 DBLb	 in	 the	 ICAM-1D1D2	 bound	 and	
unbound	forms	
(A)	Structure	of	the	 IT4var13	DBLb	domain	 in	 its	 ICAM-1	bound	form.	The	domain	 is	color	
coded	from	the	N-terminus	(blue)	to	the	C-terminus	(red).	(B)	Superposition	of	the	structure	
of	the	IT4var13	DBLb	in	its	unbound	(bright	green)	and	ICAM-1	bound	(dark	green)	forms.	(C)	
Sample	electron	density	 (feature-enhanced	2FoFc	map)	 for	 the	 ICAM-1	binding	site	 in	 the	
IT4var13	DBLb-ICAM-1D1D2	complex,	contoured	at	a	sigma	level	of	1.0.	Dashed	lines	indicate	
hydrogen	bonds.	(D)	Crystal	contacts	around	the	flexible	loop	of	the	ICAM-1	binding	site	(red)	
between	symmetry	mates	(green	and	bright	green)	in	the	crystals	of	the	unbound	IT4var13	
DBLb	domain.	Dashed	lines	 indicate	hydrogen	bonds.	For	orientation,	the	residue	F1113	is	
indicated.	 	
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Figure	 S2	 –	 SPR	analysis	 of	 potential	 conformational	 changes	upon	 receptor	binding	 for	
DBLb	and	CIDRa	domains	
Domains	were	injected	over	their	respective	receptors	at	a	fixed	concentration	of	3µM.	For	
each	injection,	the	association	time	was	varied	in	60s	intervals	between	60s	and	240s.	The	
data	 were	 then	 superimposed	 using	 the	 end	 of	 the	 injection	 as	 a	 fixed	 time	 point	 and	
normalized	by	setting	the	signal	at	the	start	of	the	injection	to	0	and	at	the	end	of	the	injection	
to	100,	 to	monitor	how	the	dissociation	 rate	changes	with	 the	 length	of	association	 time.	
DBLb	domains	were	injected	over	ICAM-1D1D5–Fc	immobilized	on	a	CM5	chip	pre-coupled	with	
Protein	A.	CIDRa	domains	were	injected	over	biotinylated	EPCR	immobilized	on	a	CAP	sensor	
chip.	 	
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Figure	S3	–	CD	spectroscopy	and	melting	curves	for	IT4var13	DBLb	wild	type	and	mutants	
(A)	Secondary	structure	analysis	of	the	IT4var13	DBLb	wild	type	(wt)	domain	and	mutants.	CD	
spectra	were	recorded	at	20°C	between	wavelengths	of	195	nm	and	260	nm.	For	each	sample,	
four	measurements	were	averaged	and	corrected	 for	buffer	absorption.	 (B)	 Thermal	melt	
analysis	of	IT4var13	DBLb	wild	type	and	mutant	domains.	CD	spectra	were	recorded	between	
200	 nm	 and	 250	 nm	 and	 after	 each	measurement	 the	 temperature	was	 raised	 by	 0.5°C.	
Shown	 are	 spectra	 collected	 at	 10°C	 intervals	 between	 20°C	 and	 90°C.	 (C)	 Thermal	
denaturation	 curve	 for	 IT4var13	 DBLb	 wild	 type	 and	 mutants.	 The	 ellipticity	 at	 a	 fixed	
wavelength	of	222	nm	was	measured	between	20°C	and	90°C.	After	each	measurement,	the	
temperature	was	increased	by	0.5°C.	A	dashed	line	indicates	the	melting	point.	 	
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Figure	S4	–	CD	spectroscopy	and	melting	curves	for	J1a	DBLb	wild	type	and	mutants	
(A)	Secondary	 structure	 analysis	 of	 the	 J1a	DBLb	wild	 type	 (wt)	 domain	 and	mutants.	 CD	
spectra	were	recorded	at	20°C	between	wavelengths	of	195	nm	and	260	nm.	For	each	sample,	
four	measurements	were	averaged	and	corrected	 for	buffer	absorption.	 (B)	 Thermal	melt	
analysis	of	J1a	DBLb	wild	type	and	mutant	domains.	CD	spectra	were	recorded	between	200	
nm	and	250	nm	and	after	each	measurement	the	temperature	was	raised	by	0.5°C.	Shown	
are	spectra	for	10°C	intervals	between	20°C	and	90°C.	(C)	Thermal	denaturation	curve	for	J1a	
DBLb	wild	type	and	mutants.	The	ellipticity	at	a	fixed	wavelength	of	222	nm	was	measured	
between	20°C	and	90°C.	After	each	measurement,	the	temperature	was	increased	by	0.5°C.	
A	dashed	line	indicates	the	melting	point.	
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Figure	S5	-	Superposition	of	the	DBLb	domains	from	IT4var13	and	PF11_0521	PfEMP1	onto	
the	DBLa	domain	from	the	varO	PfEMP1.		
IT4var13	DBLb	is	green	and	the	ICAM-1	binding	site	of	this	domain	is	red.	PF11_0521	DBLb	is	
yellow	and	the	ICAM-1	binding	site	of	this	domain	is	pink.	The	varO	DBLa	domain	(PDB	2XU0)	
(38)	is	grey.	The	superposition	was	made	using	PyMol.	 	
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Figure	S6.	Crysol	fits	for	DBLb-ICAM-1D1D2	models	generated	by	HADDOCK	and	comparison	
with	the	crystal	structures	
(A)	 Crysol	 fits	 between	 SAXS	 data	 and	 the	 top	 models	 for	 DBLb	 –ICAM-1D1D2	 complexes	
selected	after	SAXS	filtering.	The	models	for	(B)	the	PF11_0521	DBLb-ICAM-1D1D2	(DBLb:	dark	
yellow;	ICAM-1D1D2:	red)	and	(C)	the	IT4var13	DBLb	–	ICAM-1D1D2	(DBLb:	green;	ICAM-1D1D2:	
blue)	 complexes	 derived	 from	 HADDOCK	 after	 SAXS-filtering	 are	 superimposed	 over	 the	
crystal	structures	of	the	respective	complexes	(grey).		 	
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Figure	S7	–	SAXS	analysis	of	DBLb-ICAM-1D1D2	complexes	
Ab	initio	envelopes	calculated	from	SAXS	data	for	DBLb	domains	from	group	A	and	group	BC	
PfEMP1,	either	(A)	alone	or	(B)	in	complex	with	ICAM-1D1D2.	The	models	were	generated	by	
SwissModel	 for	 the	DBLb	domains	alone	or	by	HADDOCK	 for	 the	DBLb	domains	bound	 to	
ICAM-1D1D2	and	were	docked	into	the	envelopes	using	Chimera.	 	
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Table	S1	Sequences	used	for	phylogenetic	analyses	
	
PfEMP1	 GenBank	accession	number	 ICAM-1	binding	phenotype	shown	in	
IT4var01	 AAO67411	 (28,	29)	
IT4var02	 AAQ73925	 (28,	29)	
IT4var02_D8	 AAQ73925	 (29)	
IT4var06	 ABM88781	 (28,	29)	
IT4var07	 ABM88782	 (30)	
IT4var07_D5	 ABM88782	 (28,	29)	
IT4var08	 ABM88783	 (28,	29)	
IT4var11	 ETW15085	 (29)	
IT4var12	 AAB06961	 (28,	29)	
IT4var13	 ABM88750	 (28,	29,	49)	
IT4var14	 AAD03351	 (28,	29)	
IT4var15	 AAA75398	 (28,	29)	
IT4var16	 AAS89259	 (28,	29,	49)	
IT4var17	 ABM88751	 (28,	29)	
IT4var18	 ABM88752	 (28,	29)	
IT4var19	 ABM88753	 (28,	29)	
IT4var20	 AAA75397	 (28,	29)	
IT4var22	 ABM88754	 (28,	29)	
IT4var27	 ABM88759	 (28,	29,	49)	
IT4var31	 AAF18980	 (28,	29,	49)	
IT4var35	 ADK78857	 (28,	29)	
IT4var41	 ABM88768	 (28,	29,	49)	
IT4var44	 ABM88769	 (29)	
IT4var64	 ABM88780	 (29)	
Bc12a	 AVI24062	 (27)	
J1a	 AVI24063	 (27)	
PCM7	 AVI24066	 (27)	
JDP8	 AAK49742	 (75)	
PF08_0140	 XP_001349512	 (22)	
 43 
PF08_0141	 XP_001349513	 (22)	
PF11_0521	 XP_001348176	 (22,	46)	
PF11_008	 XP_001347692	 (22,	26)	
PF13_0003_D8	 XP_001349740	 (22)	
PFD1235w	 XP_002808895	 (22,	26)	
PFD1235w_D5	 XP_002808895	 (22,	26)	
PFD0020c	 EWC90558	 (22)	
HB3var01	 KOB61483	 (22)	
HB3var03	 KOB63865	 (22)	
HB3var1CSA	 KOB61785	 (22)	
HB3var05_D7	 KOB63865	 (22)	
Dd2var25	 KOB84767	 (22)	
DD2var32	 KOB85388	 (22,	26)	
Dd2var52	 ABM88780	 (22)	
JF712902	 AEQ26010	 (22,	26)	
JF712903	 AEA86277	 (22,	26)	
JF712900	 JF712900	 (22,	26)	
JF712901	 JF712901	 (22,	26)	
KF984156	 AIX97102	 (22)	
KM364031	 AIY25809	 (22)	
KM364034	 AIY25811	 (22)	
KM364033	 AIY25810	 (22)	
KJ866957	 AIX97164	 (22)	
KJ866958	 AIX97165	 (22)	
KJ866959	 AIX97166	 (22)	
JQ691646	 AFJ66676	 (22)	
JQ691647	 AFJ66677	 (22)	
JQ691649	 AFJ66679	 (22)	
AFJ66668	 AFJ66668	 (22)	
JN037695	 AEI26313	 (22)	
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Table	S2	–	List	of	contacts	between	IT4var13DBLb	and	ICAM-1D1D2	
Colors	correspond	to	those	used	in	Fig.	2	of	the	main	text.	 
	
IT4var13	DBLb	 ICAM-1D1D2	 	
Residue	 Group	 Residue	 Group	 Type	of	Interaction	
Asn973	 Sidechain	NH2	 Arg166	 Backbone	O	 Hydrogen	bond	
Asn974	 Sidechain	NH2	 Arg167	 Backbone	O	 Hydrogen	bond	
Glu1098	 Sidechain	O	 Arg49	 Sidechain	NH2	 Hydrogen	bond	
Leu1102	 Sidechain	 Leu44	 Sidechain	 Hydrophobic	
Leu1102	 Sidechain	 Val51	 Sidechain	 Hydrophobic	
Gln1103	 Sidechain	O	 Leu18	 Backbone	N	 Hydrogen	bond	
Gln1103	 Sidechain	NH2	 Leu18	 Backbone	O	 Hydrogen	bond	
Ile1106	 Sidechain	 Leu18	 Sidechain	 Hydrophobic	
Ser1112	 Backbone	N	 Ile10	 Backbone	O	 Hydrogen	bond	
Ser1112	 Backbone	O	 Ile10	 Backbone	N	 Hydrogen	bond	
Phe1113	 Sidechain	 Val9	 Sidechain	 Hydrophobic	
Phe1113	 Sidechain	 Leu11	 Sidechain	 Hydrophobic	
Phe1113	 Sidechain	 Val17	 Sidechain	 Hydrophobic	
Gly1114	 Backbone	N	 Lys8	 Backbone	O	 Hydrogen	bond	
Gly1114	 Backbone	O	 Lys8	 Backbone	N	 Hydrogen	bond	
Gln1121	 Sidechain	NH2	 Gly169	 Backbone	O	 Hydrogen	bond	
Leu1139	 Sidechain	 Leu42	 Sidechain	 Hydrophobic	
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Table	S3	–	Kinetic	parameters	derived	from	SPR	for	binding	of	ICAM-1D1D5	to	IT4var13	DBLb	
wild	type	and	mutants	
	
Interaction	
ka1		
(x105	M-1	s-1)	
kd1		
(10-2	s-1)	
ka2		
(x10-2	s-1)	
kd2		
(10-4	s-1)	
	KD		
(nM)	
ICAMD1D5		-	IT4var13	DBLb	wt	 6.47	 7.76	 1.13	 1.17	 1.22	
ICAMD1D5		-	IT4var13	DBLb	N973A	 36.40	 60.80	 1.66	 3.24	 3.22	
ICAMD1D5		-	IT4var13	DBLb	N974A	 64.00	 99.22	 1.53	 3.02	 2.99	
ICAMD1D5		-	IT4var13	DBLb E1098A	 4.26	 9.37	 1.21	 7.82	 13.40	
ICAMD1D5		-	IT4var13	DBLb	L1102D	 0.21	 2.46	 0.54	 10.91	 196.00	
ICAMD1D5		-	IT4var13	DBLb	Q1103A	 0.09	 1.47	 0.43	 8.98	 259.00	
ICAMD1D5		-	IT4var13	DBLb I1106D	 0.80	 87.74	 0.28	 452.40	 10300.00	
ICAMD1D5		-	IT4var13	DBLb	F1113A	 0.05	 3.71	 0.11	 10.31	 3620.00	
ICAMD1D5		-	IT4var13	DBLb	Q1121A	 13.60	 8.49	 1.49	 2.11	 0.86	
ICAMD1D5		-	IT4var13	DBLb L1139D	 3.19	 6.07	 1.18	 5.89	 9.06	
	 	 	 	 	 	
ICAMD1D5		-	IT4var13	DBLb	G1115A	 8.28	 8.37	 0.56	 1.25	 2.21	
ICAMD1D5		-	IT4var13	DBLb	G1114/5A	 630.00	 685.00	 3.07	 3.12	 1.09	
ICAMD1D5		-	IT4var13	DBLb	G1114/5/6A	 7.96	 7.54	 0.43	 0.85	 1.86	
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Table	S4	-	Kinetic	parameters	derived	from	SPR	for	binding	of	ICAM-1D1D5	to	J1a	DBLb	wild	
type	and	mutants 
	
Interaction	
ka1		
(x104	M-1	s-1)	
kd1		
(10-2	s-1)	
ka2		
(x10-3	s-1)	
kd2		
(10-4	s-1)	
	KD		
(nM)	
ICAMD1D5		-	J1a	DBLb	wt	 1.75	 2.54	 4.26	 9.40	 262.00	
ICAMD1D5		-	J1a	DBLb	L1093D	 1.07	 1.07	 3.54	 10.64	 232.00	
ICAMD1D5		-	J1a	DBLb L1096D	 0.74	 2.55	 3.20	 10.81	 866.00	
ICAMD1D5		-	J1a	DBLb	Y1097A	 0.08	 3.45	 3.46	 4.74	 5140.00	
ICAMD1D5		-	J1a	DBLb	Y1115A	 0.16	 3.73	 7.93	 1.71	 498.00	
ICAMD1D5		-	J1a	DBLb	G1117A	 4.27	 44.15	 4.48	 1.51	 336.00	
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Table	S5	-	Parameters	derived	from	solution	scattering	data	
	
	 Rg		
(nm)	
Dmax	
(nm)	
Vporod	
(nm3)	
Mrexp		
(kDa)	
Mrapp	
(kDa)	
DBLb	domain	alone	
PF11_0521	DBLb	 27.30	 94.12	 84.0	 49.80	 57.20	
PFD1235w	DBLb	 26.80	 86.43	 85.0	 50.00	 56.90	
KF984156	DBLb	 28.00	 88.07	 86.9	 51.12	 57.90	
IT4var13	DBLb	 26.00	 89.35	 85.8	 50.47	 55.60	
Bc12a	DBLb	 26.00	 88.64	 78.6	 46.26	 54.60	
J1a	DBLb	 26.40	 85.86	 79.0	 47.00	 53.60	
DBLb-ICAMD1D2	
PF11_0521	DBLb	–	ICAM-1D1D2	 35.11	 126.10	 140.0	 89.4	 82.00	
PFD1235w	DBLb	–	ICAM-1D1D2	 35.21	 128.07	 132.0	 90.0	 82.00	
KF984156	DBLb	–	ICAM-1D1D2	 35.33	 127.74	 139.0	 94.2	 82.00	
IT4var13	DBLb	–	ICAM-1D1D2	 32.40	 110.49	 133.0	 86.3	 82.00	
Bc12a	DBLb	–	ICAM-1D1D2	 33.74	 113.41	 115.0	 74.9	 80.00	
J1a	DBLb	–	ICAM-1D1D2	 31.08	 109.00	 98.8	 68.6	 80.00	
	
	
The	radius	of	gyration	Rg	was	determined	using	AutoRg	and	the	maximum	particle	diameter	
Dmax	was	calculated	with	GNOM.	The	Porod	volume	Vporod	was	calculated	with	PRIMUS.	
The	apparent	molecular	mass	Mrapp	was	calculated	using	the	from	the	size	and	shape	
function	in	version	2.8.3	of	the	ATSAS	suite.	Mrexp	is	the	theoretical	molecular	mass.	
